Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9N2R2 | — |
A 16 years old male patient received a dose of Shingrix.; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 16-year-old male patient who received Herpes zoster (Shingrix) (batch number 9N2R2, expiry date 25-APR-2027) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate age at vaccine administration (Verbatim: A 16 years old male patient received a dose of Shingrix.). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK Receipt Date: 22-JUL-2025 The clinic administrator reported that they administered a dose of Shingrix to a 16 year old patient, which led to inappropriate age at vaccine administration. The reporter asked that there were any long-term side effects for the patient and there was any safety information available.